Drug Profile
Octocog alfa sucrose formulation - Bayer HealthCare
Alternative Names: BAY 81-8973; BAY-14-2222; Factor VIII sucrose formulation - Bayer; Helixate FS; Helixate NexGen; Iblias; Kogenate Bayer; Kogenate FS; Kogenate PF; Kogenate SF; Kovaltry; rFVIII FSLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Developer Bayer HealthCare; CSL Behring
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilia A
Most Recent Events
- 04 Dec 2020 Adverse events and efficacy data from phase III LEOPOLD trial in Haemophilia A were presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2020)
- 27 Oct 2020 Bayer completes a phase III trial in Haemophilia A (In children, In infants, In neonates) in USA, Argentina, Austria, Canada, Bulgaria, Denmark, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russia, Serbia, Sweden and United Kingdom (IV) (NCT01311648)
- 24 Jul 2018 Registered for Haemophilia A (In adolescents, Prevention, In adults) in China (IV)